AMPLIFY-201: a lymph node-targeted, mKRAS-specific vaccine in pancreatic & colorectal cancer

24 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
In this week's episode of the VJOncoAlert Journal Club, Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, discusses results from the Phase I AMPLIFY-201 trial (NCT04853017) of the lymph node–targeted amphiphile vaccine ELI-002 2P in patients with minimal residual pancreatic or colorectal cancer harboring mKRAS mutations. Vaccination induced robust CD4+ and CD8+ T-cell responses, with evidence of antigen spreading to additional tumor-specific targets. Stronger immune responses correlated with improved relapse-free and overall survival. The findings support the potential of mKRAS-targeted vaccines to generate durable immunity and improve outcomes in gastrointestinal cancers.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo